Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 7, 2014; 20(45): 17120-17126
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17120
Published online Dec 7, 2014. doi: 10.3748/wjg.v20.i45.17120
Table 1 Demographic data of familial inflammatory bowel disease and sporadic inflammatory bowel disease
Phenotype | Familial CD (n = 17) | Sporadic CD (n = 51) | P value | Familial UC (n = 27) | Sporadic UC (n = 81) | P value |
Sex | > 0.999 | > 0.999 | ||||
Male | 14 (82.4) | 42 (82.4) | 15 (55.6) | 45 (55.6) | ||
Female | 3 (17.6) | 9 (17.6) | 12 (44.4) | 36 (44.4) | ||
Age at diagnosis | 28.2 ± 10.3 | 29.2 ± 10.5 | 0.742 | 36.2 ± 14.7 | 36.4 ± 12.8 | 0.951 |
≤ 16 yr (A1) | 0 (0) | 0 (0) | 0.849 | 0 (0) | 0 (0) | > 0.999 |
17-40 yr (A2) | 14 (82.4) | 43 (84.3) | 13 (48.1) | 39 (48.1) | ||
> 40 yr (A3) | 3 (17.6) | 8 (15.7) | 14 (51.9) | 42 (51.9) | ||
Age at symptom onset, yr | 22.6 ± 9.5 | 23.5 ± 9.3 | 0.438 | 36.2 ± 14.5 | 36.7 ± 12.7 | 0.710 |
Main symptom at diagnosis | ||||||
Abdominal pain | 10 (58.8) | 32 (62.7) | 0.773 | 5 (18.5) | 30 (37.0) | 0.098 |
Diarrhea | 5 (29.4) | 16 (31.4) | 0.880 | 11 (40.7) | 22 (27.2) | 0.232 |
Weight loss | 0 (0.0) | 2 (3.9) | > 0.999 | 0 (0.0) | 0 (0.0) | > 0.999 |
Fever | 0 (0.0) | 1 (2.0) | > 0.999 | 0 (0.0) | 0 (0.0) | > 0.999 |
Abdominal mass | 0 (0.0) | 0 (0.0) | > 0.999 | 0 (0.0) | 0 (0.0) | > 0.999 |
Hematochezia | 2 (11.8) | 9 (17.6) | 0.718 | 21 (77.8) | 66 (81.5) | 0.780 |
EIM | 0 | 3 | 10 | 19 | ||
Somatitis | 0 (0.0) | 0 (0.0) | > 0.999 | 0 (0.0) | 2 (2.5) | 0.061 |
Arthritis and arthralgia | 0 (0.0) | 2 (4.2) | > 0.999 | 1 (3.7) | 8 (9.9) | 0.445 |
Erythema nodosum | 0 (0.0) | 1 (2.1) | > 0.999 | 4 (14.8) | 5 (6.2) | 0.223 |
Episcleritis | 0 (0.0) | 0 (0.0) | > 0.999 | 5 (18.5) | 4 (4.9) | 0.042 |
Table 2 Comparison of location/extent and behavior of disease between familial and sporadic inflammatory bowel disease using the Montreal classification n (%)
Type of IBD | Familial CD (n = 17) | Sporadic CD (n = 51) | P value | Familial UC (n = 27) | Sporadic UC (n = 81) | P value |
Location/extent1 | ||||||
1 | 3 (17.6) | 11 (21.6) | > 0.999 | 11 (40.7) | 28 (34.6) | 0.645 |
2 | 2 (11.8) | 9 (17.6) | 0.718 | 15 (55.5) | 47 (58.0) | 0.826 |
3 | 12 (70.6) | 31 (60.8) | 0.568 | 1 (3.8) | 6 (7.4) | 0.677 |
4 | 0 (0.0) | 0 (0.0) | > 0.999 | |||
CD behavior2 | 0.668 | |||||
1 | 9 (52.9) | 33 (64.7) | 0.391 | |||
2 | 3 (17.6) | 8 (15.7) | > 0.999 | |||
3 | 5 (29.5) | 10 (19.6) | 0.504 | |||
Perianal fistula | 4 (23.5) | 12 (23.5) | > 0.999 |
Table 3 Comparison of clinical characteristics between familial and sporadic inflammatory bowel disease n (%)
Familial CD (n = 17) | Sporadic CD (n = 51) | P value | Familial UC (n = 27) | Sporadic UC (n = 81) | P value | |
Disease activity (at diagnosis) | CDAI | Mayo score | ||||
Mean ± SD | 120.5 ± 68.2 | 107.8 ± 82.1 | 0.207 | 3.6 ± 2.0 | 3.7 ± 1.8 | 0.673 |
< 150 | 11 (64.7) | 36 (70.6) | 0.761 | 0-2, 9 (33.3) | 18 (22.2) | 0.428 |
150 ≤ and < 220 | 4 (23.5) | 8 (15.7) | 3-5, 14 (51.9) | 52 (64.2) | ||
≥ 220 | 2 (11.8) | 7 (13.7) | 6-12, 4 (14.8) | 11 (13.6) | ||
No. of hospitalizations | 0.175 | 0.794 | ||||
0 | 9 (52.9) | 35 (68.6) | 25 (92.6) | 73 (90.1) | ||
1-2 | 6 (35.2) | 14 (27.5) | 1 (3.7) | 7 (8.7) | ||
≥ 3 | 2 (11.7) | 2 (3.9) | 1 (3.7) | 1 (1.2) | ||
No. of relapses | 0.342 | 0.333 | ||||
0 | 13 (76.5) | 44 (86.3) | 22 | 72 | ||
1-2 | 4 (23.5) | 7 (13.7) | 5 | 9 | ||
≥ 3 | 0 (0.0) | 0 (0.0) | 0 | 0 | ||
Relapse duration after diagnosis, mo | 49.3 ± 65.5 | 38.9 ± 44.5 | 0.907 | 58.2 ± 102.2 | 21.3 ± 20.5 | 0.898 |
Follow-up duration after diagnosis, mo | 84 (24-312) | 36 (8-240) | 0.008 | 96 (12-240) | 60 (12-85) | 0.170 |
Table 4 Comparison of number of bowel resection surgeries between familial and sporadic inflammatory bowel disease n (%)
Phenotype | Familial CD (n = 17) | Sporadic CD (n = 51) | P value | Familial UC (n = 27) | Sporadic UC (n = 81) | P value |
Number of surgeries | 0.194 | 0.759 | ||||
0 | 13 (76.5) | 44 (86.3) | 27 (100) | 79 (97.5) | ||
1 | 3 (17.6) | 7 (13.7) | 0 (0.0) | 2 (2.5) | ||
2 | 1 (5.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Table 5 Medication types and adverse events in patients with familial and sporadic inflammatory bowel disease n (%)
Familial CD (n = 17) | Sporadic CD (n = 51) | P value | Familial UC (n = 27) | Sporadic UC (n = 81) | P value | |
5-ASA | 16 (94.1) | 50 (98.0) | > 0.999 | 17 (63.0) | 64 (79.0) | 0.124 |
Steroid | 7 (41.2) | 15 (29.4) | 0.551 | 5 (18.5) | 18 (22.2) | 0.684 |
Thiopurines | 7 (41.2) | 28 (54.9) | 0.406 | 5 (18.5) | 11 (13.6) | 0.540 |
Anti-TNF antibodies | 3 (17.6) | 0 (0.0) | 0.014 | 0 (0.0) | 0 (0.0) | - |
Suppository | ||||||
5-ASA | 1 (5.9) | 0 | 0.250 | 3 (11.1) | 1 (1.2) | 0.047 |
Steroid | 0 | 2 (3.9) | > 0.999 | 18 (66.7) | 35 (43.2) | 0.035 |
AEs by thiopurine | 4 (23.5) | 8 (15.7) | 0.477 | 1 (3.7) | 6 (7.4) | 0.677 |
Leukopenia | 4 (23.5) | 7 (13.7) | 0.448 | 1 (3.7) | 4 (4.9) | > 0.999 |
Nausea | 0 | 1 (2.0) | > 0.999 | 0 (0.0) | 0 (0.0) | > 0.999 |
Arthralgia | 0 | 0 | > 0.999 | 0 (0.0) | 1 (1.2) | > 0.999 |
Skin lesion | 0 | 0 | > 0.999 | 0 (0.0) | 1 (1.2) | > 0.999 |
Pancreatitis | 0 | 0 | > 0.999 | 0 | 0 | > 0.999 |
Elevation of liver enzyme | 0 | 0 | > 0.999 | 0 | 0 | > 0.999 |
- Citation: Chung SH, Park SJ, Lee HS, Hong SP, Cheon JH, Kim TI, Kim WH. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea. World J Gastroenterol 2014; 20(45): 17120-17126
- URL: https://www.wjgnet.com/1007-9327/full/v20/i45/17120.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i45.17120